HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eberly, L. E. Search for Related Content PubMed PubMed Citation Articles by Eberly, L. E. Social Bookmarking                What's this?

Metabolic Syndrome

Risk factor distribution and 18-year mortality in the Multiple Risk Factor Intervention Trial

¹ Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota
² School of Medicine, Wake Forest University, Winston-Salem, North Carolina
³ School of Medicine, St. Louis University, St. Louis, Missouri
⁴ Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania

Address correspondence and reprint requests to Dr. L.E. Eberly, Division of Biostatistics, School of Public Health, University of Minnesota, 420 Delaware St., SE, MMC 303, Minneapolis, MN 55455-0378. E-mail: lynn{at}biostat.umn.edu

OBJECTIVE—To examine the long-term association of metabolic syndrome with mortality among those at high risk for cardiovascular disease (CVD).

RESEARCH DESIGN AND METHODS—A total of 10,950 Multiple Risk Factor Intervention Trial (MRFIT) survivors were followed for mortality an additional median 18.4 years (1980–1999). Proportional hazards models examined multivariate-adjusted risks associated with Adult Treatment Panel III–defined metabolic syndrome conditions, with BMI substituted for waist circumference.

RESULTS—At MRFIT annual visit 6, 4,588 (41.9%) men, mean age (±SD) 53.0 ± 5.9 years, had metabolic syndrome and 6,362 did not. Comparing men with metabolic syndrome to men without, adjusted hazard ratios (HRs) were 1.21 (95% CI 1.13–1.29), 1.49 (1.35–1.64), and 1.51 (1.34–1.70) for 18-year total, CVD, and coronary heart disease mortality, respectively. Among men with metabolic syndrome, elevated glucose (1.54 [1.34–1.78]) and low HDL cholesterol (1.45 [1.17–1.54]) were most predictive of CVD mortality, followed by elevated BMI (1.34 [1.17–1.54]), elevated blood pressure (1.25 [0.98–1.58]), and elevated triglycerides (1.06 [0.86–1.30]). In contrast, for men without metabolic syndrome, the HR for low HDL cholesterol was 1.02 (0.86–1.22). Among metabolic syndrome men with no nonfatal CVD event, smokers with elevated LDL cholesterol showed higher CVD mortality (1.79 [1.22–2.63]) compared with nonsmokers without elevated LDL cholesterol; this additional risk was even greater for metabolic syndrome men with a nonfatal CVD event (2.11 [1.32–3.38]).

CONCLUSIONS—Metabolic syndrome is associated with an increased risk of mortality. Among those with metabolic syndrome, risk is further increased by having more metabolic syndrome conditions, by cigarette smoking, and by elevated LDL cholesterol. Primary prevention of each metabolic syndrome condition should be emphasized, and presence of each condition should be treated in accordance with current guidelines.

Abbreviations: ATP-III, Adult Treatment Panel III • CHD, cooronary heart disease • CVD, cardiovascular disease • DBP, diastolic blood pressure • MRFIT, Multiple Risk Factor Intervention Trial • SBP, systolic blood pressure

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Monami, C. Lamanna, D. Balzi, F. Bartalucci, C. Melani, G. Masotti, N. Marchionni, and E. Mannucci Metabolic Syndrome and Cardiovascular Mortality in Older Type 2 Diabetic Patients: A Longitudinal Study J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2008; 63(6): 646 - 649. [Abstract] [Full Text] [PDF]

				W. S. Fenton and M. R. Chavez Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia Focus, January 1, 2008; 6(2): 246 - 253. [Abstract] [Full Text] [PDF]

				J. A. Morrison, L. A. Friedman, and C. Gray-McGuire Metabolic Syndrome in Childhood Predicts Adult Cardiovascular Disease 25 Years Later: The Princeton Lipid Research Clinics Follow-up Study Pediatrics, August 1, 2007; 120(2): 340 - 345. [Abstract] [Full Text] [PDF]

				R. Kahn Metabolic Syndrome: Is It a Syndrome? Does It Matter? Circulation, April 3, 2007; 115(13): 1806 - 1811. [Full Text] [PDF]

				R. S. Beaser and P. Levy A Work in Progress, but a Useful Construct Circulation, April 3, 2007; 115(13): 1812 - 1818. [Full Text] [PDF]

				W. S. Fenton and M. R. Chavez Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia Am J Psychiatry, October 1, 2006; 163(10): 1697 - 1704. [Full Text] [PDF]

				N. Ishizaka, Y. Ishizaka, H. Hashimoto, E.-I. Toda, R. Nagai, and M. Yamakado Metabolic Syndrome May Not Associate With Carotid Plaque in Subjects With Optimal, Normal, or High-Normal Blood Pressure Hypertension, September 1, 2006; 48(3): 411 - 417. [Abstract] [Full Text] [PDF]

				R. Kahn The Metabolic Syndrome (Emperor) Wears No Clothes Diabetes Care, July 1, 2006; 29(7): 1693 - 1696. [Full Text] [PDF]

				R. H. Eckel, R. Kahn, R. M. Robertson, and R. A. Rizza Preventing Cardiovascular Disease and Diabetes: A call to action from the American Diabetes Association and the American Heart Association Diabetes Care, July 1, 2006; 29(7): 1697 - 1699. [Full Text] [PDF]

				R. H. Eckel, R. Kahn, R. M. Robertson, and R. A. Rizza Preventing Cardiovascular Disease and Diabetes: A Call to Action From the American Diabetes Association and the American Heart Association Circulation, June 27, 2006; 113(25): 2943 - 2946. [Full Text] [PDF]